Can a Blood Pressure Medication Help HD Patients?
Can rilmenidine delay disease progression in Huntington's disease? Cambridge researchers are trying to find out.
Celebrating 50 Years of the Huntington's Disease Society of America
Louise Vetter discusses 50 years of the HDSA, and insight as to why she continues to fight on behalf of families affected by Huntington's disease.
Gene Therapy for HD Continues to Show Promise
The administration of AMT-130 into the mouse striatum led to significant improvements in motor symptoms and survival.
Louise Vetter Previews "Her Mother's Daughter" and Stresses Storytelling in Rare
Louise Vetter stresses the importance of storytelling in rare diseases, and why film is such a powerful tool to convey messages that need to be heard.
Marjorie Guthrie's Impact on Rare Disease Advocacy
In this video, Louise Vetter, President and CEO of the HDSA talks about Marjorie Guthrie’s impact on the rare disease community and the creation of NORD.
Can a Ganglioside Stop Huntington's Disease
Intracerebroventricular infusion of GM1 resulted in numerous improvements in neuropathology, behavior, and cognition in HD mice models
Gene Therapy for HD Gets FDA Orphan Designation
AMT-130 has a AAV5 vector carrying an artificial micro-RNA designed to silence the mutant huntingtin gene.
Are HD Clinical Trials Measuring the Right Outcome Measure?
A new study recently published in
may have found a solution to the factors limiting HD clinical trials.
NIH Awards $2.5 Million Grant to HD Wearables
HDWear, a technology that utilizes sensors to monitor motor function of Huntington’s disease patients, has received more than $2.5 million from the NIH.
Global HD Organizations Launch Collaborative Advocacy Group
Three global Huntington’s disease patient advocacy organizations have teamed up to give those affected by the disease a voice in clinical research.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.